3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
Shares of US biotech Moderna jumped to nearly $108 on Wednesday after the firm revealed encouraging data for its cancer vaccine, mRNA-4157. 11 April 2024
Singapore-based contract research organization (CRO) Novotech has released an expert report, Acute Myeloid Leukemia - Global Clinical Trial Landscape, offering critical data-backed analysis of the latest developments in acute myeloid leukemia (AML) research. 11 April 2024
Shares of Seattle, USA-based biotech Alpine Immune Sciences 20% on a takeover rumor by Bloomberg, and leapt a further 36% pre-market to $64.10 when the speculation was confirmed. 11 April 2024
US clinical-stage biotech Rallybio Corporation saw its shares leap 76% to $2.87 pre-market today, after it revealed a collaboration with healthcare giant Johnson & Johnson. 11 April 2024
The US Food and Drug Administration has given a green light to BrainStorm Cell Therapeutics for the design of a Phase IIIb trial of NurOwn (MSC-NTF cells). 10 April 2024
Los Angeles, USA-based TORL BioTherapeutics, a biotech focused on discovering and developing antibody-based immunotherapies, has closed an oversubscribed $158 million Series B-2 financing. 10 April 2024
Antibody drug conjugates (ADCs) are currently in vogue with investors and big pharma, as a rapidly emerging class of therapeutic agents that combine the target specificity of a monoclonal antibody with the lethality of cytotoxic cellular poison. 10 April 2024
Swiss ophthalmology firm Oculis Holding today announced the appointment of Dr Snehal Shah, executive leader with over two decades of research and development (R&D) and regulatory experience, to the role of president of R&D. 10 April 2024
There has been an uptick in licensing agreements for drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology over the past five years, notes GlobalData. 10 April 2024
Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer, has appointed a new chief scientific officer. 9 April 2024
The biopharmaceutical industry is currently facing pressure from expiring patents, which are expected to result in a $100 billion headwind for the industry over the next five years. 9 April 2024
Seaport Therapeutics has become the latest founded entity to be created by PureTech Health, the Boston-based biotech behind Karuna Therapeutics, which was recently acquired by Bristol Myers Squibb for $14 billion. 9 April 2024
Increasing interest in targeted therapies is driving demand in the antibody discovery market, finds industry analyst Future Market Insights. 8 April 2024
Two frequent words that people often hear in recent China’s pharma industry comments are “Chu Hai” and “Nei Juan”. The former means “selling overseas,” while the latter means “cut throat competition.” 8 April 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.